These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10792268)

  • 1. Management of cerebral vasculopathy in children with sickle cell anaemia.
    Powars DR
    Br J Haematol; 2000 Mar; 108(4):666-78. PubMed ID: 10792268
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyurea in the treatment of sickle cell associated priapism.
    Al Jam'a AH; Al Dabbous IA
    J Urol; 1998 May; 159(5):1642. PubMed ID: 9554374
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
    Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
    Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease.
    Mack AK; Thompson AA
    J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 6. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
    DeBaun MR
    Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.
    Helton KJ; Wang WC; Wynn LW; Khan RB; Steen RG
    AJNR Am J Neuroradiol; 2002; 23(10):1692-6. PubMed ID: 12427625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
    Suliman H; Wali Y; Al Saadoon M; Zechariah M; William RR; Gujjar A; Pathare A
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):42-4. PubMed ID: 19125086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
    Madden NA; Jones GL; Kalpatthi R; Woods G
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia.
    DeBaun MR
    J Pediatr; 2005 Oct; 147(4):560-1. PubMed ID: 16227052
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospects for primary stroke prevention in children with sickle cell anaemia.
    Jordan LC; Casella JF; DeBaun MR
    Br J Haematol; 2012 Apr; 157(1):14-25. PubMed ID: 22224940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC; Cohen AR; Pressel SL; Aygun B; Imran H; Luchtman-Jones L; Thompson AA; Fuh B; Schultz WH; Davis BR; Ware RE;
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of sickle cell disease].
    de Montalembert M
    Rev Prat; 2004 Sep; 54(14):1557-64. PubMed ID: 15558966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle cell anaemia: current therapies.
    Vermylen C
    Transfus Apher Sci; 2013 Oct; 49(2):151-4. PubMed ID: 23954416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the crisis of care for sickle-cell disease.
    Morris K
    Lancet; 1999 May; 353(9163):1504. PubMed ID: 10232329
    [No Abstract]   [Full Text] [Related]  

  • 16. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
    Ware R
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
    [No Abstract]   [Full Text] [Related]  

  • 17. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
    Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
    Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in management of sickle cell disease.
    Agarwal MB
    Indian J Pediatr; 2003 Aug; 70(8):649-54. PubMed ID: 14510086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.